Summary
The use of replication-competent oncolytic viruses has largely advanced cancer gene therapy. Oncolytic virus not only possesses unique mechanisms of action that are distinct from other treatment modalities, its self-perpetuating nature provides an ideal platform for therapeutic transgene insertion. Tumor selectivity can be achieved by deleting viral genes that are critical for growth in normal cells but dispensable in tumor cells, transcriptional control under tumor-specific promoters, fiber modification targeting tumor-specific cellular receptors, or the use of inherent tumor-specific viruses. Transgene products can be amplified along with viral replication, thus maximizing therapeutic effect. Using adenovirus as a template, this chapter describes common assays used for the study of oncolytic viruses, with special emphasis on in vitro and in vivo viral replication determination.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
O’Reilly, D. R., Muller, L. K. and Luckow, V. A. (1994) Baculovirus Expression Vectors: A Laboratory Manual, Oxford University Press, pp. 132–34.
Liu, T. C., Hallden, G., Wang, Y., Brooks, G., Francis, J., Lemoine, N. and Kirn, D. (2004) An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 9, 786–803.
Reed, L. and Muench, h. (1938) A simple method for estimating fifty percent endpoints. Am J Hyg 27, 858–63.
Wang, Y., Thorne, S., Hannock, J., Francis, J., Au, T., Reid, T., Lemoine, N., Kirn, D. and Hallden, G. (2005) A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 11, 351–60.
Bancroft, J.D. and Gamble M. (Ed). (2002) Theory and Practice of Histological Techniques (5th Edition), Churchill Livingstone, pp. 63–139.
Edinger, M., Sweeney, T. J., Tucker, A. A., Olomu, A. B., Negrin, R. S. and Contag, C. h. (1999) Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1, 303–10.
Le, L. P., Li, J., Ternovoi, V. V., Siegal, G. P. and Curiel, D. T. (2005) Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J Gen Virol 86, 3201–8.
Zhao, h., Doyle, T. C., Coquoz, O., Kalish, F., Rice, B. W. and Contag, C. h. (2005) Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt 10, 41210.
Iyer, M., Salazar, F. B., Lewis, X., Zhang, L., Wu, L., Carey, M. and Gambhir, S. S. (2005) Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res 14, 47–55.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Liu, TC., Thorne, S.H., Kirn, D.H. (2008). Oncolytic Adenoviruses for Cancer Gene Therapy. In: Gene Therapy Protocols. Methods in Molecular Biology™, vol 433. Humana Press. https://doi.org/10.1007/978-1-59745-237-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-59745-237-3_15
Publisher Name: Humana Press
Print ISBN: 978-1-58829-903-1
Online ISBN: 978-1-59745-237-3
eBook Packages: Springer Protocols